Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a multiple ascending dose study of exidavnemab in Parkinson’s disease and multiple system atrophy
2024-511222-30-00Phase 2Completed
- Sponsor
- BioArctic
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of exidavnemab in Parkinson's disease (PD) and multiple system atrophy (MSA) (5 arms), sponsored by BioArctic. Primary endpoint: Safety and tolerability after 4 treatment cycles. Started Sep 2024; status: completed.
02
Drugs
exidavnemab
03
Conditions
Parkinson's disease (PD)multiple system atrophy (MSA)
Beyond the preview
Go deeper on 2024-511222-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511222-30-00.